Shoulder Innovations Gets FDA Clearance for New Titanium Shoulder Implant

Key Facts

1Shoulder Innovations received U.S. FDA 510(k) clearance for its N-22 Humeral Head system.

2The new implant is a titanium option designed specifically for patients with metal hypersensitivity.

3The company has initiated a full commercial launch of the product following the regulatory clearance.

In a move that strengthens its position in the specialized med-tech market, Shoulder Innovations announced it has received U.S. FDA 510(k) clearance for its N-22 Humeral Head system. The new implant, constructed from titanium, is specifically designed for patients with metal hypersensitivity, providing surgeons with a critical alternative for shoulder arthroplasty procedures. Following the regulatory clearance, the company has initiated an immediate full commercial launch of the product.

This development addresses a specific market need for patients who cannot tolerate standard implants due to allergic reactions. According to market data, SI stock closed at $19.64 on September 9, 2026, having traded between a day high of $20.29 and a day low of $19.52 during that session.

Operationally, this launch expands the company's commercial footprint within the shoulder surgical care market. Based on the price level of $19.64 at the close of September 9, 2026, market participants will be watching for the impact of this new product line on the company's revenue growth, as there are no major upcoming sector-specific catalysts in the immediate economic calendar.